Regenxbio (NASDAQ:RGNX) issued its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.04), Morningstar.com reports. Regenxbio had a negative return on equity of 9.90% and a negative net margin of 41.99%. The company had revenue of $0.88 million for the quarter.
Shares of NASDAQ:RGNX traded down $1.74 on Friday, reaching $41.98. 1,204 shares of the company’s stock were exchanged, compared to its average volume of 637,116. The company has a debt-to-equity ratio of 0.01, a quick ratio of 14.21 and a current ratio of 14.21. Regenxbio has a fifty-two week low of $38.56 and a fifty-two week high of $85.10. The stock has a market capitalization of $1.71 billion, a price-to-earnings ratio of 17.55 and a beta of 0.37.
In related news, SVP Curran Simpson sold 18,000 shares of the stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $50.00, for a total value of $900,000.00. Following the sale, the senior vice president now owns 57,500 shares of the company’s stock, valued at approximately $2,875,000. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Kenneth T. Mills sold 15,000 shares of the stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $58.53, for a total transaction of $877,950.00. Following the completion of the transaction, the chief executive officer now owns 261,000 shares of the company’s stock, valued at approximately $15,276,330. The disclosure for this sale can be found here. In the last ninety days, insiders sold 83,068 shares of company stock worth $4,342,481. Corporate insiders own 13.80% of the company’s stock.
RGNX has been the subject of several research analyst reports. Evercore ISI raised shares of Regenxbio from an “in-line” rating to an “outperform” rating and set a $51.25 price target for the company in a research report on Monday, February 25th. Zacks Investment Research downgraded shares of Regenxbio from a “buy” rating to a “hold” rating in a research note on Saturday, February 23rd. BidaskClub upgraded shares of Regenxbio from a “sell” rating to a “hold” rating in a research note on Friday, April 26th. Raymond James upgraded shares of Regenxbio from an “outperform” rating to a “strong-buy” rating and set a $94.00 price objective for the company in a research note on Tuesday, February 5th. Finally, ValuEngine downgraded shares of Regenxbio from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 10th. One analyst has rated the stock with a sell rating, three have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $78.72.
Regenxbio Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Further Reading: What is the strike price in options trading?
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.